Holland Capital invests in Health IT company Open HealthHub

Holland Capital invests in Health IT company Open HealthHub

Holland Capital invests in Health IT company Open HealthHub

Amsterdam, 26 July 2022 – Holland Capital is investing in Open HealthHub, a digital platform

that allows healthcare providers and patients to exchange medical data safely and securely. It will also reduce the administrative burden on healthcare providers. The investment will be used for the further development of the platform, building the team, and for commercial scale-up.

 

Improving data exchange in healthcare

A major challenge for the healthcare sector is sharing medical data between the patient and the healthcare provider in a safe and efficient way. Open HealthHub has developed a SaaS (Software as a Service) platform based on internationally recognized standards (FHIR), enabling different systems to be linked to each other via APIs. Using this technology a healthcare provider can easily produce digital questionnaires and intake forms for patients. For example, the medical data of a patient, registered on a smartwatch, can also be made available in the electronic patient file. While improving the provision of information for patients during or prior to a treatment process, the platform also significantly reduces the administrative burden on the healthcare providers.

 

Investment for growth

Holland Capital’s investment will be used for commercial upscaling and increasing the functionalities of Open HealthHub. The platform will be further developed so that in the future even more software applications and wearables can be linked to it.

 

Marco Woesthuis, the General Director of Open HealthHub says: “The structured recording of information and exchange between patients and healthcare providers is, in addition to hospital care, also very valuable in other healthcare sectors, such as mental health care and for general practitioners. We can significantly reduce the administrative burden on healthcare providers with our secure solutions, so that the healthcare provider can once again focus mainly on patient care. With the help of Holland Capital,  we can together continue to realize our growth objectives.”

 

Jan-Frens van Giessel, a partner of Holland Capital says: “We are proud to add Open HealthHub to our Healthcare portfolio. The open and scalable nature of the platform makes it possible to safely and efficiently exchange data between the patient and the healthcare provider, regardless of which electronic patient record is in use. This prevents data lock-in and makes care processes more efficient. We look forward to embarking on the next phase of growth together with the team.”

About Open HealthHub

Open HealthHub, founded in 2015 by Marco Woesthuis (doctor) and Martijn Verhoeven (IT entrepreneur), aims to reduce the administrative burden on healthcare providers. Open HealthHub has developed an independent digital platform where digital questionnaires and home assessments can be managed in keeping with international standards. Open HealthHub is already successfully in use at various hospitals, commercial clinics and research groups.

 

About Holland Capital

Over the past 40 years, Holland Capital has responsibly and successfully invested in over more than 150 SME-companies. With a clear investment strategy Holland Capital is active in the attractive growth markets of Healthcare and Technology. Holland Capital’s experienced and committed investment team aims to establish an open, sustainable, and professional relationship with the companies they invest in, with the common goal of achieving growth. Holland Capital is backed by a broad network of successful healthcare entrepreneurs in the relevant growth markets. www.hollandcapital.nl

 

Mauritskliniek intends to join Corius

Mauritskliniek intends to join Corius

Mauritskliniek intends to join Corius

Mauritskliniek intends to join Corius

Amsterdam, 21 July 2022 – Our portfolio company Mauritskliniek intends to join Corius. Mauritskliniek provides healthcare services in dermatology, varicose veins, proctology, skin therapy and medical-cosmetic care. The Mauritskliniek is located in Amsterdam, The Hague, Nijmegen, Utrecht and Veldhoven. Corius is the largest network of dermatology and phlebology practices in Germany and Switzerland.

By acquiring Mauritskliniek, Corius geographically expands its European healthcare offerings to the Netherlands. Both the services and vision of Mauritskliniek are perfectly consistent with those of  Corius.

Mauritskliniek intends to join Corius in the third quarter of 2022, after potential approval of the  Nederlandse Zorgautoriteit (NZa).

About Corius
Corius is a network of dermatology and phlebology practices. Doctors and partners of Corius deliver the highest level of quality and apply the most modern technology. An absolute passion for the job and patients is pivotal in the way of working. Corius offers their patients holistic and individual treatments, whereby in-house expert knowledge is shared across cross-clinics and colleagues. Employees follow additional education and trainings throughout. Corius has 32 practices and employs 139 doctors and 615 employees. About 450.000 patients are treated each year. www.corius.de

About Mauritskliniek
Mauritskliniek is a specialized clinic for dermatology, treatment for varicose veins and medical-cosmetic care. After the acquisition of Kliniek Veldhoven in 2020, the range of cosmetic-care has been further expanded. The clinics are known for high quality and a pleasant way of working. Their values are personal, clear and well organized. The clinics offer both insured and uninsured care. Customer satisfaction is rated with 8.6/10 points, according zorgkaartnederland.nl. www.maurtiskliniek.nl

About Holland Capital
Over the past 40 years, Holland Capital has responsibly and successfully invested in over more than 150 SME-companies. With a clear investment strategy Holland Capital is active in the attractive growth markets of Healthcare and Technology. Holland Capital’s experienced and committed investment team aims to establish an open, sustainable, and professional relationship with the companies they invest in, with the common goal of achieving growth. Holland Capital is backed by a broad network of successful healthcare entrepreneurs in the relevant growth markets.

Holland Capital realizes successful exit of Humeca to i4hi

Holland Capital realizes successful exit of Humeca to i4hi

Holland Capital realizes successful exit of Humeca to i4hi

Holland Capital realizes successful exit of Humeca to i4hi

Borne / Amsterdam, 5 July 2022 – Investment company Holland Capital realizes a successful exit of Humeca to fellow investor i4hi.

Humeca is a leading supplier of innovative products in the field of advanced skin grafting techniques and is the world market leader in the treatment of severe burns. The company’s internally developed revolutionary MEEK technology is superior to other transplant methods. In addition, Humeca offers various adjacent innovative products in the field of burn surgery. The company has built up a broad base of distributors serving customers in more than 70 countries worldwide with Humeca’s products.

Investment company Holland Capital offers active support

Holland Capital has been involved with Humeca as a shareholder since 2014. She has actively supported management in the strategic and commercial development of the company, including the opening of the US sales office. Hubert Verbeek, managing partner Holland Capital, about the exit: “We are extremely proud of what we have achieved together with the Humeca team over the past 8 years. We wish the team, together with i4hi, a lot of success in their next stage of growth.”

Arnoud van Velzen, managing director Humeca, “Supporting surgical burn teams and distributors worldwide in the application of our techniques is our passion. With great pride we look back on the collaboration with Holland Capital. With the participation of i4hi, we are excited to enter the next stage of growth.”